Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression

Santos‐García, Diego; Fonticoba, Teresa de Deus; Castro, Ester Suárez; Díaz, A Aneiros; Bartolomé, Carlos Cores; Panceiras, Maria J. Feal; González, Jose Manuel Paz; Aymerich, Lorena Valdés; Moreno, José Manuel García; Estrada, Marta Blázquez; Jesús, Silvia; P, Mir; Aguilar, Miquel; Planellás, Lluís; Caldentey, Juan García; Caballol, Núria; Legarda, I; Cabo, Iria; Manzanares, Lydia López; Rivera, María A. Ávila; Catalán, María José; Díaz, Luis M. López; Borrué, Carmen; Saúco, María Álvarez; Vela, Lydia; Cubo, Esther; Castrillo, Juan Carlos Martínez; Alonso, Pilar Sánchez; Losada, Maria G. Alonso; López-Ariztegui, N; Gastón, Itziar; Pascual-Sedano, Berta; Seijo, Manuel; Martínez, Javier Rúiz; Valero, Caridad; Kurtis, Mónica; Ardura, Jessica González; Jurczynska, C. Prieto; Martinez‐Martín, Pablo

doi:10.1016/j.jns.2020.117109

Cited by 13 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the score at V1, the change in the score at V2 and V3 for the BDI-II, NMSS mood/ apathy domain, and the PDQ-39 emotional well-being domain was significant too, but differences were not observed between the score from V2 and V3 to V4 for any of the scales (Table 2 and Figs. 1,2,3). With regard to the MDS-IV and Judd criteria, at the baseline visit, 2% (N = 1) of patients presented nonD, 12% (N = 6) subD, 34% (N = 17) mD, and 52% (N = 26) suffered MD.…”

Section: Resultsmentioning

confidence: 99%

“…Depression is a frequent comorbidity in PD that has a notable negative effect on health-related and global QoL of patients with PD, not only major and minor depression, but also subD [ 1 , 22 ]. Importantly, we observed that mood improvement 6 months after starting with safinamide correlated with health-related QoL improvement.…”

Section: Discussionmentioning

confidence: 99%

“…Patients were enrolled according to the following inclusion criteria: (1) diagnosis of PD according to the UK Parkinson's Disease Society Brain Bank criteria [8]; (2) to have the indication of receiving safinamide according to the neurologist criteria in their clinical practice; (3) to have a Non-Motor Symptoms Scale (NMSS) total score at baseline of at least 40; (4) no dementia criteria with a Mini-Mental State Examination at baseline of at least 26) [9]; (5) to be older than 30 years old; (6) to wish to voluntarily participate and to sign a consent form. Exclusion criteria were (1) to be under MAOB-I (rasagiline or selegiline; a washout period of at least 2 week was allowed); (2) any other contraindication to be treated with safinamide according to product data; (3) incapacity to complete the questionnaires adequately; (4) other disabling concomitant neurological disease (stroke, severe head trauma, neurodegenerative disease, etc. ); (5) other severe and disabling concomitant non-neurological disease (oncological, autoimmune, etc.…”

Section: Methodsmentioning

confidence: 99%

“…Parkinson’s disease (PD) is the second most common neurodegenerative disease, involving both motor and non-motor symptoms (NMS). Depression is a very frequent NMS that seriously affects quality of life (QoL) in PD, even in subclinical patients [ 1 ]. Treatment of mood disorders in PD is a challenging issue not only because of the poor response to medications in many patients but also the risk of adverse events and drug interactions [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

et al. 2021

View full text Add to dashboard Cite

Introduction Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson’s disease) study. Methods SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes from V1 (baseline) to V4 (6 months ± 1 month) in the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well‐being domain were analyzed. Depression was identified and classified (DSM-IV and Judd criteria) at baseline and at the end of follow-up as major depression (MD), minor depression (mD), subthreshold depression (subD), and non-depression (nonD). Results Fifty patients with PD were included (age 68.5 ± 9.12 years; 58% women; 6.4 ± 5.1 years from diagnosis) and 44 patients (88%) completed the follow-up at 6 months. The BDI-II total score was reduced by 35.9% (from 15.88 ± 10.46 at V1 to 10.18 ± 6.76 at V4; p < 0.0001). A significant decrease in the NMSS mood/apathy domain and PDQ-39 emotional well‐being domain was observed as well ( p < 0.0001). At baseline, 52% of the patients presented MD, 34% mD, 12% subD, and 2% nonD whereas at V4 the percentages were 31.8%, 34.1%, 22.7%, and 11.4%, respectively ( p = 0.029). Conclusions Safinamide improves mood in patients with PD at 6 months. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01873-w.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

et al. 2021

View full text Add to dashboard Cite

show abstract

“…QoL is considered a vital outcome indicator in patients with PD [ 29 ]. A broad list of motor and non-motor symptoms was shown to be important contributors to QoL in patients with PD [ 30 , 31 ]. In addition, cognitive impairment and severe depression were significantly correlated with poor QoL [ 32 – 34 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

et al. 2022

View full text Add to dashboard Cite

Background This study aimed to investigate the risk factors and patterns of cerebral microbleeds (CMBs) in Parkinson disease (PD) and the impact of CMBs on cognitive function and quality of life (QoL). Material/Methods Patients with PD that underwent susceptibility-weighted imaging were recruited and divided into CMB-free, lobar-CMB, deep-CMB, and mixed-CMB groups according to CMB location. Motor function (MDS-UPDRS III), cognitive abilities (MoCA, MMSE), and QoL (PDQ-39) were compared among groups. The risk factors for CMBs in patients with PD and the association between CMBs and cognition and QoL were analyzed using multivariable logistic regression models and linear regression models. Results Among the 209 patients with PD, 42 (20.1%) had CMBs. Lobar, deep, and mixed CMBs were observed in 15 (35.7%), 17 (40.5%), and 10 (23.8%) patients, respectively. A higher frequency of hypertension was independently associated with deep CMBs (odds ratio [OR]=4.379, 95% CI: 1.405–13.643, P =0.011). The deep-CMB and mixed-CMB groups had lower MoCA scores and MMSE scores than the CMB-free group, especially in domains of naming, attention, and orientation ( P <0.05). Additionally, the presence of CMBs was associated with lower MMSE (R 2 =0.140, β=−0.301, P <0.001) and MoCA (R 2 =0.104, β=−0.289, P <0.001) and higher PDQ-39 (R 2 =0.052, β=0.227, P <0.05) scores, while the association between CMBs and PDQ-39 disappeared after adjustment of MMSE or MoCA as a covariate. Conclusions The results suggest that hypertension was associated with the occurrence of deep CMBs. Comorbidity with CMBs may impair cognitive function and indirectly reduce the QoL in patients with PD.

show abstract

Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease

Mantri

Chahine

Nabieva

et al. 2021

Movement Disord Clin Pract

View full text Add to dashboard Cite

BackgroundBackground: Fatigue has a major impact on health-related quality of life (HR-QOL) in Parkinson's disease (PD). Objectives Objectives: To determine whether demographic characteristics modify the relationship between fatigue and HR-QOL. Methods Methods: Patients with PD in the Fox Insight study completed the Parkinson Fatigue Scale (PFS-16) and Geriatric Depression Scale (GDS-15). Linear regression examined the relationship between the PFS-16 and Parkinson Disease Quality of Life, as modified by age, sex, and GDS-15. Results Results: A total of 1029 participants (44% female, mean age 67.4 years, and mean disease duration 4.6 years) were included in this analysis. Multivariable regression modeling demonstrated a negative effect modification for age (β = À0.07, P < 0.001) and a positive effect modification for the GDS-15 (β = 0.057, P = 0.002), but not for sex (β = À0.021, P = 0.231). Conclusion Conclusion:The association between fatigue and worse HR-QOL is greater at younger ages and in individuals with more depressive symptoms. Targeted therapeutics for these individuals may provide the greatest impact on fatigue in PD.

show abstract

Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression

Cited by 13 publications

References 27 publications

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease

Contact Info

Product

Resources

About